Independent research tool — not a government agency. Official notices govern.Refreshed
GrantsJunctionAmerican funding, sourcedMethodology
OpenOpportunity PAR-24-311

Molecular Imaging of Inflammation in Cancer (R01 Clinical Trial Not Allowed)

National Institutes of Health · Department of Health and Human Services

At a glance

Molecular Imaging of Inflammation in Cancer (R01 Clinical Trial Not Allowed) is an open federal grant opportunity from the National Institutes of Health (Department of Health and Human Services). Applications are due January 7, 2028. Individual awards are listed as up to $500K, with $500K in total estimated funding. Applicant types listed as eligible include state governments, county governments, city or township governments, special district governments, independent school districts and 10 more. Cost sharing is not required. It is funded under Assistance Listing 93.394 (Cancer Detection and Diagnosis Research) and 2 other listings.

Summary assembled from the official notice's fields. The official notice governs.

Key facts

Posted
Nov 6, 2024
Close date
Jan 7, 2028
Archive date
Feb 12, 2028
Award floor
Not specified
Award ceiling
$500,000
Est. total funding
$500,000
Expected awards
Not specified
Cost sharing
Not required
Funding instrument
Grant
Opportunity category
Discretionary

Who can apply

  • State governments
  • County governments
  • City or township governments
  • Special district governments
  • Independent school districts
  • Public colleges & universities
  • Federally recognized tribal governments
  • Public & Indian housing authorities
  • Native American tribal organizations
  • 501(c)(3) nonprofits
  • Nonprofits without 501(c)(3) status
  • Private colleges & universities
  • For-profit organizations (not small businesses)
  • Small businesses
  • Others (see notice)

Additional information on eligibility (from the notice)

Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession; Non-domestic (non-U.S.) Entities (Foreign Organizations) are not eligible to apply. Non-domestic (non-U.S.) components of U.S. Organizations are not eligible to apply.

Based on the published notice. Review the official notice for complete eligibility requirements.

What it funds

Official synopsis as published by the agency, formatted for readability.

The purpose of this Notice of Funding Opportunity (NOFO) is to invite research grant applications (R01) for the development and use of current and emerging molecular imaging methods to gain fundamental insights into cancer inflammation in vivo.
The motivation for this initiative is that much of current imaging research into the role of inflammation in cancer is largely based on in vitro and ex vivo methods with limited utilization of imaging approaches that could lead to significant new insights relevant to dynamic cancer and inflammation interactions. Utilization of molecular imaging probes in pre-clinical and clinical investigations for precise temporal resolution at the molecular and cellular level are valuable approaches for identification and characterization of in vivo inflammatory cellular physiology in cancers and of molecular changes in response to treatment.

This FOA encourages applications that focus on developing integrated imaging approaches to interrogate the role of inflammation in cancer through strong cross-field collaboration between cancer basic science researchers and imaging scientists. These collaborations are expected to advance science and understanding of cancer inflammation interactions.

Additional information from the agency ↗

Assistance Listings

What is an ALN?

Reported obligations under ALN 93.394

Historical data · not a prediction
FY24$541M
FY25$602M
FY26$717M est.
Source: SAM.gov Assistance Listing 93.394. Program-wide totals, not awards from this specific opportunity.

Agency contact (as published)

National Institutes of Health
grantsinfo@nih.gov
301-402-2541

Quick answers

When is the deadline for “Molecular Imaging of Inflammation in Cancer (R01 Clinical Trial Not Allowed)”?

According to the official notice, applications are due January 7, 2028. Confirm the deadline and submission time on Grants.gov before applying.

Who is eligible to apply for “Molecular Imaging of Inflammation in Cancer (R01 Clinical Trial Not Allowed)”?

The official notice lists these applicant types as eligible: State governments, County governments, City or township governments, Special district governments, Independent school districts, Public colleges & universities, Federally recognized tribal governments, Public & Indian housing authorities, Native American tribal organizations, 501(c)(3) nonprofits, Nonprofits without 501(c)(3) status, Private colleges & universities and 3 more. Additional restrictions may apply; review the full notice.

How much funding is available through “Molecular Imaging of Inflammation in Cancer (R01 Clinical Trial Not Allowed)”?

Per the notice, individual awards are listed as up to $500k and total estimated program funding is $500,000.

How do I apply for “Molecular Imaging of Inflammation in Cancer (R01 Clinical Trial Not Allowed)”?

Applications are submitted through the official source, not through GrantsJunction. Open the official notice on Grants.gov (opportunity PAR-24-311), and review the full announcement and application package. Organizations applying through Grants.gov generally need an active SAM.gov registration and a Grants.gov account, which can take several weeks to set up.

Matched on shared Assistance Listings, agency, categories and eligible applicant types.